The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study

Abstract Purpose Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to determine the impact of bamlanivimab,...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of health-system pharmacy Vol. 79; no. 24; pp. 2222 - 2229
Main Authors R. Nagler, Arielle, Horwitz, Leora I, Jones, Simon, Petrilli, Christopher M, Iturrate, Eduardo, Lighter, Jennifer L, Phillips, Michael, Bosworth, Brian P, Polsky, Bruce, Volpicelli, Frank M, Dapkins, Isaac, Viswanathan, Anand, François, Fritz, Kalkut, Gary
Format Journal Article
LanguageEnglish
Published 05.12.2022
Online AccessGet full text

Cover

Loading…
Abstract Abstract Purpose Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to determine the impact of bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab on clinical outcomes within 30 days of COVID-19 diagnosis. Methods A retrospective cohort study was conducted at a single academic medical center with 3 campuses in Manhattan, Brooklyn, and Long Island, NY. Patients 12 years of age or older who tested positive for COVID-19 or were treated with a COVID-19–specific therapy, including COVID-19 mAb therapies, at the study site between November 24, 2020, and May 15, 2021, were included. The primary outcomes included rates of emergency department (ED) visit, inpatient admission, intensive care unit (ICU) admission, or death within 30 days from the date of COVID-19 diagnosis. Results A total of 1,344 mAb-treated patients were propensity matched to 1,344 patients with COVID-19 patients who were not treated with mAb therapy. Within 30 days of diagnosis, among the patients who received mAb therapy, 101 (7.5%) presented to the ED and 79 (5.9%) were admitted. Among the patients who did not receive mAb therapy, 165 (12.3%) presented to the ED and 156 (11.6%) were admitted (relative risk [RR], 0.61 [95% CI, 0.50-0.75] and 0.51 [95% CI, 0.40-0.64], respectively). Four mAb patients (0.3%) and 2.64 control patients (0.2%) were admitted to the ICU (RR, 01.51; 95% CI, 0.45-5.09). Six mAb-treated patients (0.4%) and 3.37 controls (0.3%) died and/or were admitted to hospice (RR, 1.61; 95% CI, 0.54-4.83). mAb therapy in ambulatory patients with COVID-19 decreases the risk of ED presentation and hospital admission within 30 days of diagnosis.
AbstractList Abstract Purpose Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to determine the impact of bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab on clinical outcomes within 30 days of COVID-19 diagnosis. Methods A retrospective cohort study was conducted at a single academic medical center with 3 campuses in Manhattan, Brooklyn, and Long Island, NY. Patients 12 years of age or older who tested positive for COVID-19 or were treated with a COVID-19–specific therapy, including COVID-19 mAb therapies, at the study site between November 24, 2020, and May 15, 2021, were included. The primary outcomes included rates of emergency department (ED) visit, inpatient admission, intensive care unit (ICU) admission, or death within 30 days from the date of COVID-19 diagnosis. Results A total of 1,344 mAb-treated patients were propensity matched to 1,344 patients with COVID-19 patients who were not treated with mAb therapy. Within 30 days of diagnosis, among the patients who received mAb therapy, 101 (7.5%) presented to the ED and 79 (5.9%) were admitted. Among the patients who did not receive mAb therapy, 165 (12.3%) presented to the ED and 156 (11.6%) were admitted (relative risk [RR], 0.61 [95% CI, 0.50-0.75] and 0.51 [95% CI, 0.40-0.64], respectively). Four mAb patients (0.3%) and 2.64 control patients (0.2%) were admitted to the ICU (RR, 01.51; 95% CI, 0.45-5.09). Six mAb-treated patients (0.4%) and 3.37 controls (0.3%) died and/or were admitted to hospice (RR, 1.61; 95% CI, 0.54-4.83). mAb therapy in ambulatory patients with COVID-19 decreases the risk of ED presentation and hospital admission within 30 days of diagnosis.
PURPOSEDespite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to determine the impact of bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab on clinical outcomes within 30 days of COVID-19 diagnosis. METHODSA retrospective cohort study was conducted at a single academic medical center with 3 campuses in Manhattan, Brooklyn, and Long Island, NY. Patients 12 years of age or older who tested positive for COVID-19 or were treated with a COVID-19-specific therapy, including COVID-19 mAb therapies, at the study site between November 24, 2020, and May 15, 2021, were included. The primary outcomes included rates of emergency department (ED) visit, inpatient admission, intensive care unit (ICU) admission, or death within 30 days from the date of COVID-19 diagnosis. RESULTSA total of 1,344 mAb-treated patients were propensity matched to 1,344 patients with COVID-19 patients who were not treated with mAb therapy. Within 30 days of diagnosis, among the patients who received mAb therapy, 101 (7.5%) presented to the ED and 79 (5.9%) were admitted. Among the patients who did not receive mAb therapy, 165 (12.3%) presented to the ED and 156 (11.6%) were admitted (relative risk [RR], 0.61 [95% CI, 0.50-0.75] and 0.51 [95% CI, 0.40-0.64], respectively). Four mAb patients (0.3%) and 2.64 control patients (0.2%) were admitted to the ICU (RR, 01.51; 95% CI, 0.45-5.09). Six mAb-treated patients (0.4%) and 3.37 controls (0.3%) died and/or were admitted to hospice (RR, 1.61; 95% CI, 0.54-4.83). mAb therapy in ambulatory patients with COVID-19 decreases the risk of ED presentation and hospital admission within 30 days of diagnosis.
Author Polsky, Bruce
Jones, Simon
Bosworth, Brian P
Lighter, Jennifer L
Iturrate, Eduardo
Viswanathan, Anand
François, Fritz
R. Nagler, Arielle
Petrilli, Christopher M
Kalkut, Gary
Horwitz, Leora I
Phillips, Michael
Volpicelli, Frank M
Dapkins, Isaac
Author_xml – sequence: 1
  givenname: Arielle
  surname: R. Nagler
  fullname: R. Nagler, Arielle
– sequence: 2
  givenname: Leora I
  surname: Horwitz
  fullname: Horwitz, Leora I
– sequence: 3
  givenname: Simon
  surname: Jones
  fullname: Jones, Simon
– sequence: 4
  givenname: Christopher M
  surname: Petrilli
  fullname: Petrilli, Christopher M
– sequence: 5
  givenname: Eduardo
  surname: Iturrate
  fullname: Iturrate, Eduardo
– sequence: 6
  givenname: Jennifer L
  surname: Lighter
  fullname: Lighter, Jennifer L
– sequence: 7
  givenname: Michael
  surname: Phillips
  fullname: Phillips, Michael
– sequence: 8
  givenname: Brian P
  surname: Bosworth
  fullname: Bosworth, Brian P
– sequence: 9
  givenname: Bruce
  surname: Polsky
  fullname: Polsky, Bruce
– sequence: 10
  givenname: Frank M
  surname: Volpicelli
  fullname: Volpicelli, Frank M
– sequence: 11
  givenname: Isaac
  surname: Dapkins
  fullname: Dapkins, Isaac
– sequence: 12
  givenname: Anand
  surname: Viswanathan
  fullname: Viswanathan, Anand
– sequence: 13
  givenname: Fritz
  surname: François
  fullname: François, Fritz
– sequence: 14
  givenname: Gary
  surname: Kalkut
  fullname: Kalkut, Gary
BookMark eNotkMtqwzAUREVJoUnaXT9Ayy7q5lryS92F9BUIZJN2K2T5mijYkmvJpenX1yFZzTAMw3BmZGKdRULuY3iKQfCFOuy7xd-v0kykV2QapzyNmACYjB5yETEo2A2ZeX8AiFkB2ZTI3R6paTulA3U1XW2_1i9RLGjrrNONs6qhygZTusqgp85S3Rhr9Bi7IWjXon-mS9pj6J3vUAfzg1S7vesD9WGojrfkulaNx7uLzsnn2-tu9RFttu_r1XITaQ5ZiHKox2-lwKLETJVJpbMiVQzy0VR5BilTseBZxhCUAMxyUSgsEpFAoaHgjM_Jw3m36933gD7I1niNTaMsusFLlrN0XEgYH6uP56oeP_sea9n1plX9UcYgTxzliaO8cOT_AAFpKQ
CitedBy_id crossref_primary_10_7326_M22_1286
crossref_primary_10_1177_10600280231222465
Cites_doi 10.1056/NEJMoa2108163
10.1038/nature02145
10.1016/j.ajem.2021.07.050
10.1056/NEJMoa2107934
10.1093/infdis/jiab377
10.1126/science.abe2402
10.7326/M16-2607
10.1056/NEJMoa2109682
10.18637/jss.v042.i07
10.1038/s41586-020-2349-y
10.1080/19420862.2021.1919285
10.1093/cid/ciab912
10.1002/sim.6880
10.1056/NEJMoa2035002
10.1001/jama.2021.0202
10.1038/s41586-020-2772-0
10.1056/NEJMoa2029849
10.1186/s40001-021-00524-8
10.1016/j.eclinm.2021.101102
10.1056/NEJMoa2102685
10.1172/JCI151697
ContentType Journal Article
DBID AAYXX
CITATION
7X8
DOI 10.1093/ajhp/zxac295
DatabaseName CrossRef
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
Pharmacy, Therapeutics, & Pharmacology
EISSN 1535-2900
EndPage 2229
ExternalDocumentID 10_1093_ajhp_zxac295
GroupedDBID ---
.XZ
04C
0R~
23M
36B
4.4
48X
5GY
5RE
5RS
5WD
6J9
6PF
AABZA
AACZT
AAIMJ
AAPQZ
AAPXW
AARHZ
AAUAY
AAVAP
AAWTL
AAYEP
AAYXX
ABCQX
ABDBF
ABJNI
ABMNT
ABNHQ
ABPQP
ABPTD
ABQNK
ABWST
ABXVV
ACFRR
ACGFO
ACIWK
ACPRK
ACUTJ
ACYHN
ADBBV
ADGKP
ADGZP
ADIPN
ADOJX
ADQBN
ADRTK
ADVEK
AEGXH
AELWJ
AENEX
AETBJ
AFFZL
AFGWE
AFRAH
AFXAL
AGINJ
AGQXC
AGUTN
AIAGR
AJEEA
ALMA_UNASSIGNED_HOLDINGS
ATGXG
BCRHZ
BEYMZ
BMSDO
C45
CITATION
CS3
EAD
EAP
EAS
EBC
EBD
EBS
ECF
ECT
ECV
EHN
EIHBH
EJD
EMB
EMK
EMOBN
ENC
ENERS
EPL
EPT
EST
ESX
EX3
F5P
FECEO
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
H13
IAO
IHR
INH
INR
J5H
KOP
KSI
KSN
L7B
M5~
MHKGH
MK0
MV1
NLBLG
NOMLY
NOYVH
O9-
OAUYM
OB4
OBOKY
OCZFY
ODMLO
OFXIZ
OJZSN
OPAEJ
OVD
OVIDX
OWPYF
P2P
PONUX
Q~Q
R0Z
RHI
ROX
RUSNO
SJN
SV3
TEORI
TMA
TSH
TUS
VVN
WH7
WOW
WQ9
YFH
YOC
YXANX
7X8
ID FETCH-LOGICAL-c306t-70f082b9e8be6ab4dc685a207dc6d76052a193662e0a90e6798ae849408c08323
ISSN 1079-2082
IngestDate Fri Oct 25 05:45:53 EDT 2024
Mon Oct 14 04:03:30 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 24
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c306t-70f082b9e8be6ab4dc685a207dc6d76052a193662e0a90e6798ae849408c08323
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://academic.oup.com/ajhp/article-pdf/79/24/2222/47562243/zxac295.pdf
PQID 2725193423
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_2725193423
crossref_primary_10_1093_ajhp_zxac295
PublicationCentury 2000
PublicationDate 2022-12-05
PublicationDateYYYYMMDD 2022-12-05
PublicationDate_xml – month: 12
  year: 2022
  text: 2022-12-05
  day: 05
PublicationDecade 2020
PublicationTitle American journal of health-system pharmacy
PublicationYear 2022
References Weinreich (2022120508530948400_CIT0009) 2021; 384
Benton (2022120508530948400_CIT0002) 2020; 588
VanderWeele (2022120508530948400_CIT0023) 2017; 167
Dougan (2022120508530948400_CIT0005) 2021; 385
Liu (2022120508530948400_CIT0026) 2021; 13
Weinreich (2022120508530948400_CIT0015) 2021; 385
Arpino (2022120508530948400_CIT0017) 2016; 35
Li (2022120508530948400_CIT0003) 2003; 426
Sekhon (2022120508530948400_CIT0021) 2011; 42
Gupta (2022120508530948400_CIT0011) 2021; 385
Ganesh (2022120508530948400_CIT0013) 2021; 131
Cannas (2022120508530948400_CIT0020) 2019
Gottlieb (2022120508530948400_CIT0007) 2021; 325
SeyedAlinaghi (2022120508530948400_CIT0016) 2021; 26
Chen (2022120508530948400_CIT0008) 2021; 384
Razonable (2022120508530948400_CIT0014) 2021; 40
O’Brien (2022120508530948400_CIT0006) 2021; 385
Centers for Disease Control and Prevention (2022120508530948400_CIT0027)
Baum (2022120508530948400_CIT0001) 2020; 370
Pinto (2022120508530948400_CIT0004) 2020; 583
R Core Team (2022120508530948400_CIT0019) 2019
Dougan (2022120508530948400_CIT0010) 2021; 75
Pearl (2022120508530948400_CIT0022) 2000
Ganesh (2022120508530948400_CIT0024) 2021; 224
Ash (2022120508530948400_CIT0025) 2021; 50
Kreuzberger (2022120508530948400_CIT0012) 2021; 9
Chen (2022120508530948400_CIT0018) 2018
References_xml – volume: 385
  start-page: e81
  issue: 23
  year: 2021
  ident: 2022120508530948400_CIT0015
  article-title: REGEN-COV antibody combination and outcomes in outpatients with Covid-19
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2108163
  contributor:
    fullname: Weinreich
– volume: 426
  start-page: 450
  issue: 6965
  year: 2003
  ident: 2022120508530948400_CIT0003
  article-title: Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
  publication-title: Nature
  doi: 10.1038/nature02145
  contributor:
    fullname: Li
– year: 2018
  ident: 2022120508530948400_CIT0018
  contributor:
    fullname: Chen
– volume: 50
  start-page: 129
  year: 2021
  ident: 2022120508530948400_CIT0025
  article-title: Real world utilization of REGEN-COV2 at a community hospital
  publication-title: Am J Emerg Med
  doi: 10.1016/j.ajem.2021.07.050
  contributor:
    fullname: Ash
– volume: 385
  start-page: 1941
  issue: 21
  year: 2021
  ident: 2022120508530948400_CIT0011
  article-title: Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2107934
  contributor:
    fullname: Gupta
– volume: 224
  start-page: 1278
  issue: 8
  year: 2021
  ident: 2022120508530948400_CIT0024
  article-title: Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiab377
  contributor:
    fullname: Ganesh
– volume: 370
  start-page: 1110
  issue: 6520
  year: 2020
  ident: 2022120508530948400_CIT0001
  article-title: REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
  publication-title: Science
  doi: 10.1126/science.abe2402
  contributor:
    fullname: Baum
– year: 2019
  ident: 2022120508530948400_CIT0020
  contributor:
    fullname: Cannas
– volume: 167
  start-page: 268
  issue: 4
  year: 2017
  ident: 2022120508530948400_CIT0023
  article-title: Sensitivity analysis in observational research: introducing the E-value
  publication-title: Ann Intern Med
  doi: 10.7326/M16-2607
  contributor:
    fullname: VanderWeele
– volume: 385
  start-page: 1184
  issue: 13
  year: 2021
  ident: 2022120508530948400_CIT0006
  article-title: Subcutaneous REGEN-COV antibody combination to prevent Covid-19
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2109682
  contributor:
    fullname: O’Brien
– volume: 42
  start-page: 1
  issue: 7
  year: 2011
  ident: 2022120508530948400_CIT0021
  article-title: Multivariate and propensity score matching software with automated balance optimization: the matching package for R
  publication-title: J Stat Softw
  doi: 10.18637/jss.v042.i07
  contributor:
    fullname: Sekhon
– volume: 583
  start-page: 290
  issue: 7815
  year: 2020
  ident: 2022120508530948400_CIT0004
  article-title: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
  publication-title: Nature
  doi: 10.1038/s41586-020-2349-y
  contributor:
    fullname: Pinto
– volume-title: Causality: Models, Reasoning, and Inference
  year: 2000
  ident: 2022120508530948400_CIT0022
  contributor:
    fullname: Pearl
– volume: 13
  start-page: 1919285
  issue: 1
  year: 2021
  ident: 2022120508530948400_CIT0026
  article-title: 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro
  publication-title: MAbs
  doi: 10.1080/19420862.2021.1919285
  contributor:
    fullname: Liu
– volume: 75
  start-page: e440
  issue: 1
  year: 2021
  ident: 2022120508530948400_CIT0010
  article-title: A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciab912
  contributor:
    fullname: Dougan
– volume: 35
  start-page: 2074
  issue: 12
  year: 2016
  ident: 2022120508530948400_CIT0017
  article-title: Propensity score matching with clustered data. An application to the estimation of the impact of caesarean section on the Apgar score
  publication-title: Stat Med
  doi: 10.1002/sim.6880
  contributor:
    fullname: Arpino
– volume: 384
  start-page: 238
  issue: 3
  year: 2021
  ident: 2022120508530948400_CIT0009
  article-title: REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2035002
  contributor:
    fullname: Weinreich
– volume: 325
  start-page: 632
  issue: 7
  year: 2021
  ident: 2022120508530948400_CIT0007
  article-title: Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial
  publication-title: JAMA
  doi: 10.1001/jama.2021.0202
  contributor:
    fullname: Gottlieb
– volume: 588
  start-page: 327
  issue: 7837
  year: 2020
  ident: 2022120508530948400_CIT0002
  article-title: Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion
  publication-title: Nature
  doi: 10.1038/s41586-020-2772-0
  contributor:
    fullname: Benton
– volume: 384
  start-page: 229
  issue: 3
  year: 2021
  ident: 2022120508530948400_CIT0008
  article-title: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2029849
  contributor:
    fullname: Chen
– volume: 26
  start-page: 51
  issue: 1
  year: 2021
  ident: 2022120508530948400_CIT0016
  article-title: Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review
  publication-title: Eur J Med Res
  doi: 10.1186/s40001-021-00524-8
  contributor:
    fullname: SeyedAlinaghi
– volume: 9
  start-page: CD013825
  year: 2021
  ident: 2022120508530948400_CIT0012
  article-title: SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19
  publication-title: Cochrane Database Syst Rev
  contributor:
    fullname: Kreuzberger
– volume: 40
  start-page: 101102
  year: 2021
  ident: 2022120508530948400_CIT0014
  article-title: Casirivimab-imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2021.101102
  contributor:
    fullname: Razonable
– volume-title: R: A Language and Environment for Statistical Computing
  year: 2019
  ident: 2022120508530948400_CIT0019
  contributor:
    fullname: R Core Team
– volume: 385
  start-page: 1382
  issue: 15
  year: 2021
  ident: 2022120508530948400_CIT0005
  article-title: Bamlanivimab plus etesevimab in mild or moderate Covid-19
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2102685
  contributor:
    fullname: Dougan
– volume: 131
  start-page: e151697
  issue: 19
  year: 2021
  ident: 2022120508530948400_CIT0013
  article-title: Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19
  publication-title: J Clin Invest
  doi: 10.1172/JCI151697
  contributor:
    fullname: Ganesh
– ident: 2022120508530948400_CIT0027
  contributor:
    fullname: Centers for Disease Control and Prevention
SSID ssj0012806
Score 2.4151912
Snippet Abstract Purpose Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more...
PURPOSEDespite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data...
SourceID proquest
crossref
SourceType Aggregation Database
StartPage 2222
Title The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study
URI https://search.proquest.com/docview/2725193423
Volume 79
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbK9oKEJhggdkNGgr1k7hzXuZi3bGMaiMsEHdpb5CQODJWm6lKJ7UfxGzmOnThFfRi8pFFUO63Pp-PLOd93EHoJa4KMytInSlBOuK98IkZUkcgPVFgyVcomiebDx_Dsgr-7DC4Hg9-9rKVFnQ3z25W8kv-xKjwDu2qW7D9YtusUHsA92BeuYGG43tnGjuZ4_Onr2xPiCw_eX-WT5ogPxu0qq3SmoI4KdDTIalHD7zHpcIk3V_W8aimXni6ZO697urOtRm0b2-mJTRgWJTFy0N7MyGB3h_Sfh-C8v1mqYQJ78snEwUhLDze1ZL33CmDoTm-76gFfrn66HIGm8tfEcLl7ggj2MNceW7CmggoNep6WRgKMaSoPDVXrfQPCBKV992xqzVgYMt53toyx3sStK5OvnBSMYJb88X0GH7e_ZM5MXc9l9e2_ZsUuV9FE6Uepbp_a1vfQOgPHBh51PTk6OTrt4lY6Tm2yXM2fs1QLaH-o2x_a9suLoOU1QLOwGT9EG3ZHghMDr0dooKabaP_c2vIAjx1D7_oA7-NzJ3Z-s4kemHNfbOhsj1EKX8cGk7gqcYtJ7DCJHSZxNcUtJnGLydc4wUuIxAaRuEHkE3Rx-mZ8fEZsEQ-Sw260JhEtYRwyoeJMhTLjRR7GgWQ0gpsigs00k-AvwpApKgVVOigoVcwFp3EO2wM2eorWpgC8ZwhrqcSY8VKTyblgMi6KKBfQL_OLUjC6hV61o5rOjFZLusp6W-hFO-QpOFMdIZNTVS2uUxZpIrcWxdy-Y1876L5D9y5aq-cLtQfL1Dp7brHxB4_DmOI
link.rule.ids 315,783,787,27936,27937
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+impact+of+COVID-19+monoclonal+antibodies+on+clinical+outcomes%3A+A+retrospective+cohort+study&rft.jtitle=American+journal+of+health-system+pharmacy&rft.au=R.+Nagler%2C+Arielle&rft.au=Horwitz%2C+Leora+I&rft.au=Jones%2C+Simon&rft.au=Petrilli%2C+Christopher+M&rft.date=2022-12-05&rft.issn=1079-2082&rft.eissn=1535-2900&rft.volume=79&rft.issue=24&rft.spage=2222&rft.epage=2229&rft_id=info:doi/10.1093%2Fajhp%2Fzxac295&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_ajhp_zxac295
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-2082&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-2082&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-2082&client=summon